This announcement is a separate document:
カイオム・バイオサイエンス：ヒト化DLK-1抗体・レンバチニブ併用に関する日本における特許査定についてのお知らせ
Chiome Bioscience: Announcements of individual stocks regarding patent assessments in Japan for the combination of humanized DLK-1 antibody and lenvatinib.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated